Skip to main content
Mabpharm Limited logo

Mabpharm Limited — Investor Relations & Filings

Ticker · 2181 ISIN · KYG5780F1046 HKEX Manufacturing
Open in API
Filings indexed 221 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2181

About Mabpharm Limited

http://www.mabpharm.cn

Mabpharm Limited is a biopharmaceutical company focused on the research, development, production, and commercialization of monoclonal antibody (mAb) drugs and biosimilars. The core therapeutic areas include oncology (cancer) and autoimmune diseases. The company emphasizes bringing high-quality, affordable, and innovative biological drugs to the market by utilizing efficient R&D systems and low-cost manufacturing capabilities. Its robust pipeline features multiple candidates, including 9 monoclonal antibody drugs and 1 strong antibody drug.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing for an equity issuer listed on the Hong Kong Stock Exchange, detailing movements in authorized share capital, issued shares, treasury shares, share options, and public float sufficiency confirmation. It is a regulatory compliance report related to share capital and shareholding movements, not a financial report, earnings release, or management discussion. The document is structured as a formal submission to the exchange with no financial statements or management commentary. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about share capital and shareholding status under exchange rules, and does not match other more specific categories like Share Issue/Capital Change (SHA) because it reports no changes during the month. The document length and content confirm it is not a brief announcement but a regulatory compliance report.
2026-05-06 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 26, 2026
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a form of proxy for the Annual General Meeting, sent to shareholders to appoint proxies and cast votes on resolutions. This is part of the materials soliciting votes ahead of the AGM rather than the AGM presentation itself or the formal meeting minutes. It matches the definition of Proxy Solicitation & Information Statement (PSI).
2026-04-27 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal notice convening the Annual General Meeting, detailing resolutions to be voted on, proxy appointment instructions, record dates, and meeting logistics. It is sent to shareholders to provide information and solicit their votes rather than presenting post-meeting materials or the actual AGM presentation. This fits the definition of Proxy Solicitation & Information Statement (PSI).
2026-04-27 English
PROPOSED RE-ELECTION OF DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND PROPOSED RE-APPOINTMENT OF AUDITOR AND PROPOSED ADOPTION OF NEW MEMORANDUM AND
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a shareholder circular containing a notice of Annual General Meeting, detailed resolutions for re-election of directors, share repurchase and issuance mandates, auditor re-appointment, and amendments to the constitutional documents, along with proxy form instructions and explanatory appendices. It is clearly a solicitation of shareholder votes and an information statement for the meeting rather than the full annual report or the meeting itself. Therefore it falls under Proxy Solicitation & Information Statement (PSI).
2026-04-27 English
2025 Annual Report
Annual Report Classification · 100% confidence The document is explicitly titled '2025 ANNUAL REPORT' and contains comprehensive sections including financial highlights, Chairman's statement, corporate profile, management discussion and analysis, and audited financial statements (consolidated statement of profit or loss, financial position, etc.). It covers the full fiscal year ended December 31, 2025, and is clearly the primary annual disclosure document for Mabpharm Limited. FY 2025
2026-04-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 95% confidence The document is an FF301 ‘Monthly Return for Equity Issuer and Hong Kong Depositary Receipts’ filed with HKEX under the Listing Rules. It details movements in share capital, issued shares, treasury shares, public float confirmation, and share option information. It is neither a financial report nor an announcement of a specific corporate action like a share buyback or dividend. Instead, it is a routine regulatory return under the exchange rules. Therefore, it falls under the general “Regulatory Filings” category.
2026-04-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.